Drug
ICG 001 clinical trials
Also written PRI-724, OP-724 and Foscenvivint.
- studies test it
- 10
- open now
- 1
- in phase 3
- 0
- first study started
- 2011
Keep track of what changes. Save the ICG 001 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
Studies by the year they started
10 studies that test it; most in 2011 (1)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 7
Kiminori Kimura, MD (5) · Prism Pharma Co., Ltd. (3) · Komagome Hospital (1) · University of Southern California (1)
Studies
Open first, then newest update. How each study uses ICG 001 is read from its arms, and is right about nine times in ten.
Testing it · 10
- A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With HemophiliaRecruitingPhase 2Kiminori Kimura, MDNCT07681089Written as Foscenvivint
- A Phase 2 Trial of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia (OP-724-H201)CompletedPhase 2Kiminori Kimura, MDNCT06144086Written as Foscenvivint
- Safety and Tolerability Study of OP-724 in Liver Cirrhosis Patients by HIV/HCV with Hemophilia.CompletedPhase 1Kiminori Kimura, MDNCT04688034Written as OP-724
- Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver CirrhosisCompletedPhase 1/2Kiminori Kimura, MDNCT03620474Written as PRI-724
- Safety, Tolerability of OP-724 in Patients With Primary Biliary Cholangitis (Phase I)CompletedPhase 1Kiminori Kimura, MDNCT04047160Written as OP-724
- An Open Label, Single Arm, Dose Escalation Phase 1 Trial of PRI-724 in Patients With HCV-induced CirrhosisCompletedPhase 1Komagome HospitalNCT02195440Written as PRI-724
- Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid MalignanciesCompletedPhase 1/2Prism Pharma Co., Ltd.NCT01606579Written as PRI-724
- Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic AdenocarcinomaCompletedPhase 1Prism Pharma Co., Ltd.NCT01764477Written as PRI-724
- Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid TumorsTerminatedPhase 1Prism Pharma Co., Ltd.NCT01302405Written as PRI-724
- Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal CancerWithdrawnPhase 2University of Southern CaliforniaNCT02413853Written as CBP/beta-catenin Antagonist PRI-724
Codes
What other systems call ICG 001 · ClinicalTrials.gg INT004702
- MeSH (NLM) C492448ICG 001One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C492448 | ICG 001 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.